The impact of COVID-19 on prescribing of pancreatic enzyme replacement therapy for people with unresectable pancreatic cancer in England. A cohort study using OpenSafely-TPP
View ORCID ProfileAgnieszka Lemanska, View ORCID ProfileColm Andrews, View ORCID ProfileLouis Fisher, Ben Butler-Cole, Amir Mehrkar, Keith J Roberts, View ORCID ProfileBen Goldacre, Alex J Walker, The OpenSAFELY Collaborative, Brian MacKenna
doi: https://doi.org/10.1101/2022.07.08.22277317
Agnieszka Lemanska
1Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
Colm Andrews
2Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
Louis Fisher
2Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
Ben Butler-Cole
2Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
Amir Mehrkar
2Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
Keith J Roberts
3Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
Ben Goldacre
2Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
Alex J Walker
2Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
Brian MacKenna
2Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
Data Availability
Detailed pseudonymised patient data are potentially re-identifiable and therefore not shared. The process for external users to request access to data via the OpenSAFELY platform is described on opensafely.org.
Posted August 31, 2022.
The impact of COVID-19 on prescribing of pancreatic enzyme replacement therapy for people with unresectable pancreatic cancer in England. A cohort study using OpenSafely-TPP
Agnieszka Lemanska, Colm Andrews, Louis Fisher, Ben Butler-Cole, Amir Mehrkar, Keith J Roberts, Ben Goldacre, Alex J Walker, The OpenSAFELY Collaborative, Brian MacKenna
medRxiv 2022.07.08.22277317; doi: https://doi.org/10.1101/2022.07.08.22277317
The impact of COVID-19 on prescribing of pancreatic enzyme replacement therapy for people with unresectable pancreatic cancer in England. A cohort study using OpenSafely-TPP
Agnieszka Lemanska, Colm Andrews, Louis Fisher, Ben Butler-Cole, Amir Mehrkar, Keith J Roberts, Ben Goldacre, Alex J Walker, The OpenSAFELY Collaborative, Brian MacKenna
medRxiv 2022.07.08.22277317; doi: https://doi.org/10.1101/2022.07.08.22277317
Subject Area
Subject Areas
- Addiction Medicine (399)
- Allergy and Immunology (708)
- Anesthesia (201)
- Cardiovascular Medicine (2936)
- Dermatology (249)
- Emergency Medicine (439)
- Epidemiology (12741)
- Forensic Medicine (12)
- Gastroenterology (827)
- Genetic and Genomic Medicine (4580)
- Geriatric Medicine (417)
- Health Economics (729)
- Health Informatics (2914)
- Health Policy (1069)
- Hematology (388)
- HIV/AIDS (924)
- Medical Education (425)
- Medical Ethics (115)
- Nephrology (468)
- Neurology (4348)
- Nursing (236)
- Nutrition (638)
- Oncology (2268)
- Ophthalmology (645)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (501)
- Pediatrics (1196)
- Primary Care Research (496)
- Public and Global Health (6933)
- Radiology and Imaging (1527)
- Respiratory Medicine (915)
- Rheumatology (437)
- Sports Medicine (385)
- Surgery (487)
- Toxicology (60)
- Transplantation (210)
- Urology (180)